- Home
- NKTR vs JRVR Comparison
NKTR vs JRVR Comparison
Compare NKTR & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | JRVR |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 288.2M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NKTR | JRVR |
|---|---|---|
| Price | $93.32 | $6.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $146.67 | $7.33 |
| AVG Volume (30 Days) | ★ 907.3K | 202.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.63% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | N/A | ★ 0.79 |
| Revenue | $307,711,000.00 | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.61 |
| P/E Ratio | ★ N/A | $8.05 |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $0.57 | $4.29 |
| 52 Week High | $109.00 | $7.20 |
Technical Indicators
Market Signals| Indicator | NKTR | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 67.84 | 45.61 |
| Support Level | $52.99 | $6.15 |
| Resistance Level | N/A | $6.39 |
| Average True Range (ATR) | 5.02 | 0.15 |
| MACD | 1.75 | 0.02 |
| Stochastic Oscillator | 56.44 | 42.74 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.